United Therapeutics Corporation Share-based Payment Arrangement, Expense
United Therapeutics Corporation (UTHR) reported Share-based Payment Arrangement, Expense of $43.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-05
- United Therapeutics Corporation share-based payment arrangement, expense for the quarter ending 2026-06-30 was $43.40M, a 14.81% increase year-over-year.
- United Therapeutics Corporation share-based payment arrangement, expense for the quarter ending 2026-03-31 was $33.90M, a 6.60% increase year-over-year.
- United Therapeutics Corporation share-based payment arrangement, expense for the quarter ending 2025-12-31 was $39.00M, a 44.44% increase year-over-year.
- United Therapeutics Corporation share-based payment arrangement, expense for the quarter ending 2025-09-30 was $39.10M, a 6.24% decline year-over-year.
- United Therapeutics Corporation share-based payment arrangement, expense for fiscal 2025 was $147.70M, a 2.57% increase from fiscal 2024.
- United Therapeutics Corporation share-based payment arrangement, expense for fiscal 2024 was $144.00M, a 268.29% increase from fiscal 2023.
- United Therapeutics Corporation share-based payment arrangement, expense for fiscal 2023 was $39.10M, a 63.39% decline from fiscal 2022.
- United Therapeutics Corporation share-based payment arrangement, expense for fiscal 2022 was $106.80M, a 22.89% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $43.40M 10-Q · filed 2026-08-05 | $77.30M 10-Q · filed 2026-08-05 | $116.30M derived: sum of 3 quarters · filed 2026-08-05 | $155.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $33.90M 10-Q · filed 2026-05-06 | $72.90M derived: sum of 2 quarters · filed 2026-05-06 | $112.00M derived: sum of 3 quarters · filed 2026-05-06 | $149.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $39.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $78.10M derived: sum of 2 quarters · filed 2026-02-25 | $115.90M derived: sum of 3 quarters · filed 2026-08-05 | $147.70M 10-K · filed 2026-02-25 |
| 2025-09-30 | $39.10M 10-Q · filed 2025-10-29 | $76.90M derived: sum of 2 quarters · filed 2026-08-05 | $108.70M 10-Q · filed 2025-10-29 | $135.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $37.80M 10-Q · filed 2026-08-05 | $69.60M 10-Q · filed 2026-08-05 | $96.60M derived: sum of 3 quarters · filed 2026-08-05 | $138.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $31.80M 10-Q · filed 2026-05-06 | $58.80M derived: sum of 2 quarters · filed 2026-05-06 | $100.50M derived: sum of 3 quarters · filed 2026-05-06 | $150.20M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $68.70M derived: sum of 2 quarters · filed 2026-02-25 | $118.40M derived: sum of 3 quarters · filed 2026-02-25 | $144.00M 10-K · filed 2026-02-25 |
| 2024-09-30 | $41.70M 10-Q · filed 2025-10-29 | $91.40M derived: sum of 2 quarters · filed 2025-10-29 | $117.00M 10-Q · filed 2025-10-29 | $133.60M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $49.70M 10-Q · filed 2025-07-30 | $75.30M 10-Q · filed 2025-07-30 | $91.90M derived: sum of 3 quarters · filed 2026-02-25 | $113.00M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $25.60M 10-Q · filed 2025-04-30 | $42.20M derived: sum of 2 quarters · filed 2026-02-25 | $63.30M derived: sum of 3 quarters · filed 2026-02-25 | $77.10M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $16.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $37.70M derived: sum of 2 quarters · filed 2026-02-25 | $51.50M derived: sum of 3 quarters · filed 2026-02-25 | $39.10M 10-K · filed 2026-02-25 |
| 2023-09-30 | $21.10M 10-Q · filed 2024-10-30 | $34.90M derived: sum of 2 quarters · filed 2024-10-30 | $22.50M 10-Q · filed 2024-10-30 | $87.30M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $13.80M 10-Q · filed 2024-07-31 | $1.40M 10-Q · filed 2024-07-31 | $66.20M derived: sum of 3 quarters · filed 2025-02-26 | $63.80M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$12.40M 10-Q · filed 2024-05-01 | $52.40M derived: sum of 2 quarters · filed 2025-02-26 | $50.00M derived: sum of 3 quarters · filed 2025-02-26 | $115.50M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $64.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $62.40M derived: sum of 2 quarters · filed 2025-02-26 | $127.90M derived: sum of 3 quarters · filed 2025-02-26 | $106.80M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$2.40M 10-Q · filed 2023-11-01 | $63.10M derived: sum of 2 quarters · filed 2023-11-01 | $42.00M 10-Q · filed 2023-11-01 | $86.70M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $65.50M 10-Q · filed 2023-08-02 | $44.40M 10-Q · filed 2023-08-02 | $89.10M derived: sum of 3 quarters · filed 2024-02-21 | $113.70M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | -$21.10M 10-Q · filed 2023-05-03 | $23.60M derived: sum of 2 quarters · filed 2024-02-21 | $48.20M derived: sum of 3 quarters · filed 2024-02-21 | $77.30M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $44.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $69.30M derived: sum of 2 quarters · filed 2024-02-21 | $98.40M derived: sum of 3 quarters · filed 2024-02-21 | $138.50M 10-K · filed 2024-02-21 |
| 2021-09-30 | $24.60M 10-Q · filed 2022-11-02 | $53.70M derived: sum of 2 quarters · filed 2022-11-02 | $93.80M 10-Q · filed 2022-11-02 | $187.50M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $29.10M 10-Q · filed 2022-08-03 | $69.20M 10-Q · filed 2022-08-03 | $162.90M derived: sum of 3 quarters · filed 2023-02-22 | $150.40M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $40.10M 10-Q · filed 2022-05-04 | $133.80M derived: sum of 2 quarters · filed 2023-02-22 | $121.30M derived: sum of 3 quarters · filed 2023-02-22 | $173.10M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $93.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $81.20M derived: sum of 2 quarters · filed 2023-02-22 | $133.00M derived: sum of 3 quarters · filed 2023-02-22 | $163.80M 10-K · filed 2023-02-22 |
| 2020-09-30 | -$12.50M 10-Q · filed 2021-11-03 | $39.30M derived: sum of 2 quarters · filed 2021-11-03 | $70.10M 10-Q · filed 2021-11-03 | $99.60M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $51.80M 10-Q · filed 2021-08-04 | $82.60M 10-Q · filed 2021-08-04 | $112.10M derived: sum of 3 quarters · filed 2022-02-24 | $136.00M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $30.80M 10-Q · filed 2021-05-05 | $60.30M derived: sum of 2 quarters · filed 2022-02-24 | $84.20M derived: sum of 3 quarters · filed 2022-02-24 | $47.00M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $29.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $53.40M derived: sum of 2 quarters · filed 2022-02-24 | $16.20M derived: sum of 3 quarters · filed 2022-02-24 | $45.40M 10-K · filed 2022-02-24 |
| 2019-09-30 | $23.90M 10-Q · filed 2020-10-28 | -$13.30M derived: sum of 2 quarters · filed 2020-10-28 | $15.90M 10-Q · filed 2020-10-28 | $18.70M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | -$37.20M 10-Q · filed 2020-07-29 | -$8.00M 10-Q · filed 2020-07-29 | -$5.20M derived: sum of 3 quarters · filed 2021-02-24 | $46.20M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $29.20M 10-Q · filed 2020-04-29 | $32.00M derived: sum of 2 quarters · filed 2021-02-24 | $83.40M derived: sum of 3 quarters · filed 2021-02-24 | $103.90M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $54.20M derived: sum of 2 quarters · filed 2021-02-24 | $74.70M derived: sum of 3 quarters · filed 2021-02-24 | -$26.40M 10-K · filed 2021-02-24 |
| 2018-09-30 | $51.40M 10-Q · filed 2019-10-30 | $71.90M derived: sum of 2 quarters · filed 2019-10-30 | -$29.20M 10-Q · filed 2019-10-30 | $89.30M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $20.50M 10-Q · filed 2019-07-31 | -$80.60M 10-Q · filed 2019-07-31 | $37.90M derived: sum of 3 quarters · filed 2020-02-26 | $13.90M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | -$101.10M 10-Q · filed 2019-05-01 | $17.40M derived: sum of 2 quarters · filed 2020-02-26 | -$6.60M derived: sum of 3 quarters · filed 2020-02-26 | -$8.50M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $118.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $94.50M derived: sum of 2 quarters · filed 2020-02-26 | $92.60M derived: sum of 3 quarters · filed 2020-02-26 | $73.50M 10-K · filed 2020-02-26 |
| 2017-09-30 | -$24.00M 10-Q · filed 2018-10-31 | -$25.90M derived: sum of 2 quarters · filed 2018-10-31 | -$45.00M 10-Q · filed 2018-10-31 | |
| 2017-06-30 | -$1.90M 10-Q · filed 2018-08-01 | -$21.00M 10-Q · filed 2018-08-01 | ||
| 2017-03-31 | -$19.10M 10-Q · filed 2018-05-02 | |||
| 2016-12-31 | $12.10M 10-K · filed 2019-02-27 | |||
| 2015-12-31 | $280.30M 10-K · filed 2018-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |